Gain Therapeutics, Inc. Stock Price, News & Analysis

Gain Therapeutics (Nasdaq: GANX) will participate in the 2025 Maxim Growth Summit on October 22–23, 2025 at The Hard Rock Hotel NYC.

Gene Mack, President and CEO, will join a live discussion on October 22 titled “Neurodegenerative Diseases Panel – Under the Radar Innovators in One of the Most Challenging Therapeutics Categories.” The panel will cover innovative approaches for neurodegenerative diseases that are currently in active clinical trials. Investors or analysts interested in a meeting with Gain management are instructed to contact their Maxim sales representative to schedule.

Gain Therapeutics (NASDAQ: GANX) will host a virtual Key Opinion Leader event titled “Biomarkers, Clinical Endpoints, and the Path to Disease Modification: Contextualizing the emerging data from GT-02287” on October 14, 2025 at 4:00 p.m. EST.

Speakers include Karl Kieburtz, M.D., M.P.H., and Kenneth Marek, M.D. Presentations will review biomarkers, clinical outcome scales, and endpoints to contextualize Phase 1b data for GT-02287 in Parkinson’s disease. The Phase 1b data presented show GT-02287 was generally well tolerated with no treatment-emergent serious adverse events and trending improvements in MDS-UPDRS scores. A live Q&A will follow the presentations.

Gain Therapeutics (NASDAQ: GANX) presented interim Phase 1b data for GT-02287 in Parkinson’s disease on October 6, 2025. Early dosing produced stability and trending improvements in MDS‑UPDRS Parts II and III by Day 90 in several participants while Part I remained unchanged.

GT-02287 was generally well tolerated with no treatment‑emergent serious adverse events, a consistent plasma PK profile within the projected therapeutic range, and DMC recommendations to continue the study. Australian authorities approved a study extension allowing treatment up to 12 months. A virtual KOL webinar is scheduled for October 14, 2025.

Gain Therapeutics (NASDAQ:GANX), a clinical-stage biotech company focused on developing next-generation allosteric small-molecule therapies, announced its participation in the Drug Discovery Innovation Programme 2025. Dr. Rinaldo Montalvão, the company's Director of Artificial Intelligence, will present a talk titled "Transforming Drug Discovery: Generative Models and Electrostatic Complementarity" during the AI and Automation in Drug Discovery track on September 26, 2025, at 9:20am CEST in Barcelona, Spain.

Gain Therapeutics (NASDAQ:GANX) has initiated a Phase 1b extension study for its Parkinson's disease treatment GT-02287, allowing participants to continue dosing for an additional nine months beyond the initial 90-day schedule. The original Phase 1b study, which enrolled 21 participants, is set to complete in December 2025.

The company will present early results from the Phase 1b study at the International Congress of Parkinson's Disease and Movement Disorders on October 7, 2025. Additional data, including MDS-UPDRS functional changes and biomarker data from cerebrospinal fluid and blood, will be available in Q4 2025. Management reports encouraging early observations regarding safety, tolerability, pharmacokinetics, and functional impact.

Gain Therapeutics (Nasdaq: GANX) has received approval from Australian authorities to extend the dosing period in its Phase 1b clinical trial of GT-02287 by an additional nine months. The extension allows participants who completed the initial 90-day treatment period to continue for up to 12 months total.

Additionally, the independent Data Monitoring Committee (DMC) has recommended continuing the study without modifications after reviewing interim safety data, finding no safety concerns. The majority of participants who completed the initial 90-day period have expressed interest in joining the extension phase.

The extended study will assess long-term safety, tolerability, functional changes according to the Movement Disorder Society Unified Parkinson's Disease Rating Scale, and biomarker activity from cerebrospinal fluid, with data intended to support Phase 2 planning.

Gain Therapeutics (NASDAQ:GANX) has reported significant progress in its Phase 1b study of GT-02287 for Parkinson's Disease. The company achieved full enrollment earlier than expected, with 16 patients enrolled as of June 30, 2025, and total enrollment not expected to exceed 20 participants.

Key financial updates include a successful public offering raising $7.1 million in net proceeds and reduced operational expenses, with R&D expenses decreasing to $2.8 million from $4.4 million year-over-year. The company's net loss improved to $0.19 per share from $0.42 per share in the previous year.

Important upcoming milestones include analysis of functional changes and biomarker activity expected in Q4 2025, potential extension of the dosing duration beyond 90 days, and an FDA IND submission planned by year-end 2025.

Gain Therapeutics (NASDAQ:GANX), a clinical-stage biotechnology company focused on developing next-generation allosteric small molecule therapies, will participate in BTIG's Annual Virtual Biotechnology Conference on July 29-30, 2025.

The company's management team will engage in a fireside chat on Wednesday, July 30, 2025, at 3:20 PM ET. Additionally, they will be available for one-on-one meetings with registered conference attendees through BTIG banking representatives.

Gain Therapeutics (Nasdaq: GANX), a clinical-stage biotech company, has announced a $7.0 million public offering of common stock and warrants. The offering consists of 4,501,640 shares at an effective price of $1.55 per share and warrants to purchase up to 2,250,820 shares at $1.65 per share.

The warrants will be exercisable immediately upon issuance with a five-year expiration term. Newbridge Securities Corporation is serving as the sole book-running manager. The proceeds will fund the development of GT-02287, their lead product candidate for treating neurodegenerative diseases, including GBA1 Parkinson's disease.